BiotechTube

Selincro® 18 mg with continuous psychosocial support: Cohort A

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Alcohol Dependence

Conditions

Alcohol Dependence

Trial Timeline

Aug 1, 2014 → Feb 1, 2016

NCT ID
NCT02195817

About Selincro® 18 mg with continuous psychosocial support: Cohort A

Selincro® 18 mg with continuous psychosocial support: Cohort A is a approved stage product being developed by Lundbeck for Alcohol Dependence. The current trial status is terminated. This product is registered under clinical trial identifier NCT02195817. Target conditions include Alcohol Dependence.

What happened to similar drugs?

10 of 20 similar drugs in Alcohol Dependence were approved

Approved (10) Terminated (2) Active (8)
✅Seroquel XRAstraZenecaApproved
✅Acamprosate or NaltrexoneMerckApproved
✅Acamprosate + PlaceboMerckApproved
✅LevetiracetamUCBApproved
✅losartan (drug)LundbeckApproved
✅nalmefeneLundbeckApproved
✅XR-NTX 380 mg, intramuscular injection + Placebo intramuscular injectionAlkermesApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02195817ApprovedTerminated

Competing Products

20 competing products in Alcohol Dependence

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
LanifibranorInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
LY686017 + PlaceboEli LillyPhase 2
35
LY3537031 + PlaceboEli LillyPhase 3
47
AD04 (ondansetron) + Matching placeboAdial PharmaceuticalsPhase 3
30
GODEX + PlaceboCelltrionPhase 3
47
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
ASP8062 + PlaceboAstellas PharmaPhase 2
35
LY686017 + PlaceboEli LillyPhase 2
35
Mazdutide + PlaceboEli LillyPhase 2
42
opioid receptor kappa antagonistEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
35
LY2196044 + placeboEli LillyPhase 2
35